CJC-1295 NO DAC (Mod GRF 1-29) (2mg)

Description

Growth hormone-releasing hormones (GHRH) are a group of endogenous protein hormones that secrete growth hormones in the body. The synthetic analog of this group of peptides is called CJC-1295. CJC-1295 peptides come in two forms, i.e., with DAC and without DAC, also known as Drug Affinity Complex.⁽¹⁾ While CJC-1295 with DAC is the exact impression of the endogenous GHRH protein, CJC-1295 no DAC peptide is a modified version of the protein. It contains four substituted amino groups that may help prevent peptide degradation and thereby prolong the peptide longevity and impact on the body. The CJC-1295 no DAC peptide is believed to bind with the serum albumin protein with the help of a free thiol group, and by creating a covalent disulfide bond. This tends to stimulate the pituitary gland, causing it to secrete a higher concentration of growth hormones in the body.⁽²⁾

Chemical Makeup ⁽¹⁾

Molecular formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular weight: 3367.9 g/mol
Other known titles: CJC-1295 Without DAC

CJC-1295 NO DAC Research

CJC-1295 (no DAC) General Research

A study⁽³⁾ was conducted to determine the efficacy of growth hormone secretagogues (GSHs) and growth hormone-releasing hormones (GHRHs), including CJC-1295 peptides, on human volunteers. The candidates were administered with peptides analogous to this class of endogenous proteins. After completing this rigorous study, it was concluded that these peptide administrations might cause enhanced growth and development, increase human appetite, and improve lean muscle mass and sleep cycle in adults. In obese patients, these peptides are also believed to reduce bone turnover. As per J.T. Sigalos et al., “Available studies indicate that these are well tolerated, with some concern for increases in blood glucose due to decreases in insulin sensitivity. Further work is needed to better understand the long-term impact of these on human anatomy and physiology, and more specifically in the context of a diversity of clinical scenarios.” (3)

CJC-1295 (no DAC) and the Intestine

Preliminary research on growth hormones suggested that these hormones may help treat common intestinal ailments such as short bowel syndrome and inflammatory bowel syndrome. However, with age, the synthesis of these hormones appears to start declining in the body, and administering them may lead to several risks. Therefore, the research on growth hormones in this arena was placed at a standstill. However, since CJC-1295 No DAC is an analog to the GHRH hormone protein, studies are ongoing to determine whether this peptide may exert similar benefits, signaling potentials for GHRH proteins at large. 

In one of the studies conducted on monkeys,⁽⁴⁾ it was seen that the CJC-1295 No DAC peptide interacts with the VPAC(1)-R receptor found on the gastric smooth muscles in the body. This interaction may improve bowel movement, which is exceptionally beneficial in common intestinal ailments, including constipation. Since this was preliminary research conducted on animals, scientists believe that these studies “demonstrate significant species differences can exist for possible therapeutic peptide agonists of the VIP/PACAP/GRF receptor family and that it is essential that receptor affinity assessments be performed in human cells or from a closely related species.”⁽⁴⁾

CJC-1295 (no DAC) and the Heart

In a preliminary study,⁽⁵⁾ experimental rats were examined after being administered with GHRH peptide analogs such as CJC-1295 without DAC. Based on the results, the peptide shows the potential to improve heart rate and blood pumping ability, especially after myocardial infarction. These studies also indicated that the peptide may promote heart tissue repair and enhance the ejection fraction rate. 

CJC-1295 (no DAC) and Growth Hormones, Thyroid

Thyroid-related ailments, including hypo- and hyper- thyroidism, are often related to poor synthesis and secretion of growth hormones in the body. To further investigate this relationship, patients suffering from hypothyroidism were closely examined before and after the thyroid replacement process.⁽⁶⁾ Aged between 25 and 60 years, fourteen patients were enrolled in this study and administered the CJC-1295 no DAC peptide. After the study’s completion, the growth hormone levels were analyzed, and it was noted that the patients appeared to respond better to the peptide after the thyroid replacement surgery. As per R Valcavi et al., “These data indicate that thyroid hormone replacement therapy enhances the responsiveness of the somatotroph to GRF 1-29 in patients with primary hypothyroidism.” ⁽⁶⁾

CJC-1295 NO DAC in Clinical Studies

CJC-1295 (no DAC), single-dose study

In this early 2000s clinical trial,⁽⁷⁾ healthy male volunteers aged between 20 and 40 were examined. All volunteers were divided into two groups; one was treated with the placebo and the other with the peptide. Blood was sampled from the candidates seven days before and after the administration of the peptide/placebo to examine the extent of growth hormone pulsatility.  After the completion of the study, it was observed that the CJC-1295 no DAC peptide appeared to cause a 7.5 fold increment in comparison to the control group. This increase was gradual throughout the study and remained unchanged for one week after stopping the peptide administration. This data suggests that the CJC-1295 no DAC peptide may have a long-lasting effect in humans.

CJC-1295 (no DAC), multi-dose study

Healthy candidates aged between 21 and 61 participated in these two-double blind ascending dose trials⁽⁸⁾ for 28 days. Candidates were divided into two groups; one group was administered with the CJC-1295 without DAC peptide and the other with a placebo. All doses were administered in four ascending doses in the first study (ascending dose) and two or three doses weekly or biweekly in the second study (increasing frequency). After the first study was completed, there appeared to be a dose-dependent increase in the concentration of growth hormones and IGF-1 for up to 10 to 11 days. The second study observed that with multiple doses of the peptide, the mean levels of the growth hormone and IGF-1 appeared to remain above baseline for up to 28 days. This study suggests that CJC-1295 without DAC may be a well-tolerated peptide with a more prolonged lasting effect of up to 8 days if given in a single dose and up to 28 days if given in multiple doses.

It should be noted that the CJC-1295 no DAC peptide is still undergoing rigorous research studies to determine its effects on human bodies fully. The peptide currently available is for educational purposes only.

References

1. National Center for Biotechnology Information. “PubChem Compound Summary for CID 91976842, CJC1295 Without DAC” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC. 
2. Sackmann-Sala, Lucila et al. “Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.” Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society vol. 19,6 (2009): 471-7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787983/  
3. Sigalos, John T, and Alexander W Pastuszak. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews vol. 6,1 (2018): 45-53. doi:10.1016/j.sxmr.2017.02.004 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632578/  
4. Ito T, Igarashi H, Pradhan TK, Hou W, Mantey SA, Taylor JE, Murphy WA, Coy DH, Jensen RT. GI side-effects of a possible therapeutic GRF analog in monkeys are likely due to VIP receptor agonist activity. Peptides. 2001 Jul;22(7):1139-51. https://pubmed.ncbi.nlm.nih.gov/11445245/ 
5. Schally AV, Zhang X, Cai R, Hare JM, Granata R, Bartoli M. Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists. Endocrinology. 2019 Jul 1;160(7):1600-1612. https://pubmed.ncbi.nlm.nih.gov/31070727/  
6. Valcavi R, Jordan V, Dieguez C, John R, Manicardi E, Portioli I, Rodriguez-Arnao MD, Gomez-Pan A, Hall R, Scanlon MF. Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine. Clin Endocrinol (Oxf). 1986 Jun;24(6):693-8. https://pubmed.ncbi.nlm.nih.gov/3098458/ 
7. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/ 
8. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683 

---

 

NOTE: These products are intended for laboratory research use only. CJC-1295 NO DAC / MOD GRF 1 29 peptide is not intended for personal use. Please review our Terms and Conditions before ordering.